These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 15651264)

  • 1. Clinical experience with drotrecogin alfa in treating gram-positive and -negative pathogens in patients with severe sepsis.
    Cone LA; Stone RA; Jesser K; Nelson R
    J Investig Med; 2004 Nov; 52(7):470-4. PubMed ID: 15651264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
    Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated).
    Micek ST; Isakow W; Shannon W; Kollef MH
    Pharmacotherapy; 2005 Jan; 25(1):26-34. PubMed ID: 15767217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results.
    Dhainaut JF; Laterre PF; LaRosa SP; Levy H; Garber GE; Heiselman D; Kinasewitz GT; Light RB; Morris P; Schein R; Sollet JP; Bates BM; Utterback BG; Maki D
    Crit Care Med; 2003 Sep; 31(9):2291-301. PubMed ID: 14501959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drotrecogin alfa (activated) in an infant with gram-negative septic shock.
    Sajan I; Da-Silva SS; Dellinger RP
    J Intensive Care Med; 2004; 19(1):51-5. PubMed ID: 15035755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of drotrecogin alfa (activated) in severe sepsis during acute pancreatitis - two case studies.
    Machała W; Wachowicz N; Komorowska A; Gaszyński W
    Med Sci Monit; 2004 Jul; 10(7):CS31-6. PubMed ID: 15232511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of activated protein C (drotrecogin alfa) in a patient with sepsis and respiratory failure on ultra high frequency jet ventilation.
    Datta D; McNamee M
    Conn Med; 2003 Jan; 67(1):11-2. PubMed ID: 12630184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
    Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; McL Booth FV
    Surgery; 2006 Nov; 140(5):726-39. PubMed ID: 17084715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drotrecogin alfa (activated) in severe falciparum malaria.
    Kendrick BJ; Gray AG; Pickworth A; Watters MP
    Anaesthesia; 2006 Sep; 61(9):899-902. PubMed ID: 16922759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.
    Ridley S; Lwin A; Wyncoll D; Lippett S; Watson D; Gunning K; Higgins D
    Eur J Anaesthesiol; 2008 Mar; 25(3):211-6. PubMed ID: 18031590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drotrecogin alfa (recombinant human activated protein C) in severe acute pancreatitis.
    Jamdar S; Siriwardena AK
    Crit Care; 2005 Aug; 9(4):321-2. PubMed ID: 16137370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated).
    Opal SM; Garber GE; LaRosa SP; Maki DG; Freebairn RC; Kinasewitz GT; Dhainaut JF; Yan SB; Williams MD; Graham DE; Nelson DR; Levy H; Bernard GR
    Clin Infect Dis; 2003 Jul; 37(1):50-8. PubMed ID: 12830408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of drotrecogin alfa (activated) in two patients with severe sepsis.
    Mikaszewska-Sokolewicz M; Nierebińska M; Mayzner-Zawadzka E
    Med Sci Monit; 2003 Aug; 9(8):CS80-7. PubMed ID: 12942037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drotrecogin alfa: a role in emergency department treatment of severe sepsis?
    McLeay AM
    Emerg Med Australas; 2004 Aug; 16(4):324-35. PubMed ID: 15283720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of heparin-induced thrombocytopenia with drotrecogin alfa (activated).
    Rubeiz GJ; Marrone CM; Leclerc JR
    Pharmacotherapy; 2006 Mar; 26(3):428-34. PubMed ID: 16503725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Severe sepsis treated with activated protein C].
    Frøyshov S; Jacobsen D; Bjertnaes L; Flaatten H
    Tidsskr Nor Laegeforen; 2004 Mar; 124(6):779-81. PubMed ID: 15039807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis.
    Dhainaut JF; Yan SB; Margolis BD; Lorente JA; Russell JA; Freebairn RC; Spapen HD; Riess H; Basson B; Johnson G; Kinasewitz GT;
    Thromb Haemost; 2003 Oct; 90(4):642-53. PubMed ID: 14515185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of drotrecogin alfa (activated) in older patients with severe sepsis.
    Alexander SL; Ernst FR
    Pharmacotherapy; 2006 Apr; 26(4):533-8. PubMed ID: 16553513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coagulopathy and the role of recombinant human activated protein C in sepsis and following polytrauma.
    Dahabreh Z; Dimitriou R; Chalidis B; Giannoudis PV
    Expert Opin Drug Saf; 2006 Jan; 5(1):67-82. PubMed ID: 16370957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.
    Davies A; Ridley S; Hutton J; Chinn C; Barber B; Angus DC
    Anaesthesia; 2005 Feb; 60(2):155-62. PubMed ID: 15644013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.